A new safety information announcement, which warns of the risk of increased blood pressure and increased heart rate with the use of Strattera (atomoxetine), has been published on the Health Canada website.
Atomoxetine should not be prescribed to patients with symptomatic cardiovascular diseases, moderate to severe hypertension or severe cardiovascular disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate, according to the information sheet released last Monday (October 24, 2011) by Eli Lilly in conjunction with Health Canada. Further information is available in the health professional notice (PDF).